Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8903 |
High Similarity |
NPD2801 |
Approved |
0.8808 |
High Similarity |
NPD1511 |
Approved |
0.879 |
High Similarity |
NPD3882 |
Suspended |
0.8718 |
High Similarity |
NPD1934 |
Approved |
0.8693 |
High Similarity |
NPD1512 |
Approved |
0.8428 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8313 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.8261 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.8193 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.8193 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.8193 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.8158 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.8155 |
Intermediate Similarity |
NPD7054 |
Approved |
0.8133 |
Intermediate Similarity |
NPD943 |
Approved |
0.8133 |
Intermediate Similarity |
NPD1240 |
Approved |
0.8117 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.8117 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.8107 |
Intermediate Similarity |
NPD7472 |
Approved |
0.8052 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.8052 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.8038 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.8026 |
Intermediate Similarity |
NPD1607 |
Approved |
0.8 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7988 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7975 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7965 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7961 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7961 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7953 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7953 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7907 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7904 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7901 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7892 |
Intermediate Similarity |
NPD919 |
Approved |
0.7871 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7866 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7861 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7844 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7831 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7831 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7812 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7806 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.78 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7758 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7751 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7719 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7706 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7697 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7683 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7673 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7651 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7643 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.763 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.761 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7605 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7562 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7543 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.753 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7516 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD5403 |
Approved |
0.75 |
Intermediate Similarity |
NPD920 |
Approved |
0.75 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7485 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7451 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7436 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7436 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7429 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7429 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7412 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7403 |
Intermediate Similarity |
NPD1008 |
Clinical (unspecified phase) |
0.7394 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7391 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7378 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7378 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7378 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7378 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7375 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7362 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.7351 |
Intermediate Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.7351 |
Intermediate Similarity |
NPD9717 |
Approved |
0.7351 |
Intermediate Similarity |
NPD9269 |
Phase 2 |
0.7349 |
Intermediate Similarity |
NPD1653 |
Approved |
0.732 |
Intermediate Similarity |
NPD1203 |
Approved |
0.7312 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7308 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7303 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7303 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7285 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7283 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7278 |
Intermediate Similarity |
NPD1933 |
Approved |
0.7257 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7251 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.725 |
Intermediate Similarity |
NPD3748 |
Approved |
0.725 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.7244 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7241 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7239 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7233 |
Intermediate Similarity |
NPD6651 |
Approved |
0.7197 |
Intermediate Similarity |
NPD411 |
Approved |
0.7195 |
Intermediate Similarity |
NPD2309 |
Approved |
0.7178 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.716 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.711 |
Intermediate Similarity |
NPD6971 |
Discontinued |
0.7108 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7101 |
Intermediate Similarity |
NPD3226 |
Approved |
0.7099 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7099 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7099 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7089 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7086 |
Intermediate Similarity |
NPD9268 |
Approved |
0.7086 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7079 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.703 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7027 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.702 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.702 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7007 |
Intermediate Similarity |
NPD228 |
Approved |
0.7006 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD9493 |
Approved |
0.6994 |
Remote Similarity |
NPD5353 |
Approved |
0.6988 |
Remote Similarity |
NPD6190 |
Approved |
0.6981 |
Remote Similarity |
NPD1296 |
Phase 2 |
0.6978 |
Remote Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.6971 |
Remote Similarity |
NPD6234 |
Discontinued |
0.697 |
Remote Similarity |
NPD2654 |
Approved |
0.6962 |
Remote Similarity |
NPD6832 |
Phase 2 |
0.6957 |
Remote Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.6951 |
Remote Similarity |
NPD2346 |
Discontinued |
0.6948 |
Remote Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.6936 |
Remote Similarity |
NPD1006 |
Clinical (unspecified phase) |
0.6923 |
Remote Similarity |
NPD5049 |
Phase 3 |
0.6923 |
Remote Similarity |
NPD7685 |
Pre-registration |
0.6913 |
Remote Similarity |
NPD1241 |
Discontinued |
0.691 |
Remote Similarity |
NPD5242 |
Approved |
0.6905 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6903 |
Remote Similarity |
NPD1608 |
Approved |
0.6872 |
Remote Similarity |
NPD2403 |
Approved |
0.6865 |
Remote Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.6854 |
Remote Similarity |
NPD5711 |
Approved |
0.6854 |
Remote Similarity |
NPD5710 |
Approved |
0.6854 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6852 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6842 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6839 |
Remote Similarity |
NPD1610 |
Phase 2 |
0.6835 |
Remote Similarity |
NPD2798 |
Approved |
0.6835 |
Remote Similarity |
NPD1019 |
Discontinued |
0.6832 |
Remote Similarity |
NPD4062 |
Phase 3 |
0.6829 |
Remote Similarity |
NPD4308 |
Phase 3 |
0.6821 |
Remote Similarity |
NPD6386 |
Approved |
0.6821 |
Remote Similarity |
NPD6385 |
Approved |
0.6802 |
Remote Similarity |
NPD824 |
Approved |
0.6792 |
Remote Similarity |
NPD3018 |
Phase 2 |
0.6782 |
Remote Similarity |
NPD37 |
Approved |
0.6776 |
Remote Similarity |
NPD405 |
Clinical (unspecified phase) |
0.6772 |
Remote Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.6772 |
Remote Similarity |
NPD1470 |
Approved |
0.677 |
Remote Similarity |
NPD3268 |
Approved |
0.6761 |
Remote Similarity |
NPD4966 |
Approved |
0.6761 |
Remote Similarity |
NPD4965 |
Approved |
0.6761 |
Remote Similarity |
NPD4967 |
Phase 2 |
0.675 |
Remote Similarity |
NPD4908 |
Phase 1 |
0.6747 |
Remote Similarity |
NPD1471 |
Phase 3 |
0.6746 |
Remote Similarity |
NPD7440 |
Discontinued |
0.6727 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6721 |
Remote Similarity |
NPD1729 |
Discontinued |
0.671 |
Remote Similarity |
NPD17 |
Approved |
0.6709 |
Remote Similarity |
NPD3225 |
Approved |
0.6706 |
Remote Similarity |
NPD7390 |
Discontinued |
0.6705 |
Remote Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.6705 |
Remote Similarity |
NPD4288 |
Approved |
0.6705 |
Remote Similarity |
NPD2296 |
Approved |
0.6703 |
Remote Similarity |
NPD7228 |
Approved |
0.6703 |
Remote Similarity |
NPD2163 |
Approved |
0.6687 |
Remote Similarity |
NPD1558 |
Phase 1 |
0.6686 |
Remote Similarity |
NPD2354 |
Approved |
0.6686 |
Remote Similarity |
NPD6844 |
Discontinued |
0.6667 |
Remote Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD8312 |
Approved |
0.6667 |
Remote Similarity |
NPD2797 |
Approved |
0.6667 |
Remote Similarity |
NPD8313 |
Approved |
0.6649 |
Remote Similarity |
NPD6104 |
Discontinued |
0.6649 |
Remote Similarity |
NPD8434 |
Phase 2 |
0.6646 |
Remote Similarity |
NPD2983 |
Phase 2 |
0.6646 |
Remote Similarity |
NPD4749 |
Approved |
0.6646 |
Remote Similarity |
NPD2982 |
Phase 2 |
0.6627 |
Remote Similarity |
NPD3892 |
Phase 2 |
0.6624 |
Remote Similarity |
NPD1201 |
Approved |
0.6615 |
Remote Similarity |
NPD4360 |
Phase 2 |
0.6615 |
Remote Similarity |
NPD4363 |
Phase 3 |
0.6614 |
Remote Similarity |
NPD6842 |
Approved |
0.6614 |
Remote Similarity |
NPD6841 |
Approved |
0.6614 |
Remote Similarity |
NPD6843 |
Phase 3 |
0.6609 |
Remote Similarity |
NPD3111 |
Phase 1 |
0.6609 |
Remote Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.6607 |
Remote Similarity |
NPD2424 |
Discontinued |
0.6603
|
Remote Similarity |
NPD1778 |
Approved |